← 返回前沿论文

蛋白酶体引导的血红素信号轴促进 T 细胞耗竭

英文原题:Proteasome-guided haem signalling axis contributes to T cell exhaustion.

PubMed 2026/03/18(内容时间) Nature Q1 · IF 56.1(JCR 2025)

研究概要

去极化线粒体的积累使T细胞走向耗竭1-3,但其确切机制仍不清楚。

中文摘要

去极化线粒体的积累使T细胞走向耗竭1-3,但其确切机制仍不清楚。本研究发现,耗竭的CD8+ T细胞因去极化线粒体积累而增强蛋白酶体活性,这驱动了线粒体蛋白的选择性降解以及通过血红素蛋白分解释放调节性血红素。反过来,调节性血红素增加会破坏BACH2介导的转录调控,从而加剧T细胞耗竭并损害干性样特性。抑制调节性血红素的核输入可防止BACH2降解,并增强抗原特异性T细胞的抗肿瘤疗效。我们发现,人CD19+嵌合抗原受体(CAR)-T细胞在B细胞急性淋巴细胞白血病患者中的治疗效果与其CAR-T细胞中的蛋白酶体基因特征呈负相关。在硼替佐米(一种FDA批准的蛋白酶体抑制剂)存在下制备CAR-T细胞可防止T细胞耗竭并提高治疗效果。我们的发现确定了一条由线粒体完整性调控的蛋白酶体引导的血红素信号轴,作为CD8+ T细胞耗竭的调节因子,并提出利用该通路优化过继性细胞免疫治疗的创新治疗策略。

展开英文摘要原文

The accumulation of depolarized mitochondria commits T cells to exhaustion 1-3 , yet the precise mechanism remains unclear. Here we find that exhausted CD8 + T cells increase proteasome activity owing to the accumulation of depolarized mitochondria, which drives the selective degradation of mitochondrial proteins and the release of regulatory haem through haemoprotein breakdown. In turn, increased regulatory haem disrupts BACH2-mediated transcriptional regulation, thereby exacerbating T cell exhaustion and compromising stemness-like properties. Inhibition of nuclear import of regulatory haem prevents BACH2 degradation and enhances the anti-tumour efficacy of antigen-specific T cells. We find that the therapeutic efficacy of human CD19 + chimeric antigen receptor (CAR)-T cells in patients with B cell acute lymphoblastic leukaemia negatively correlates with the proteasome gene signature in their CAR-T cells. Manufacturing CAR-T cells in the presence of bortezomib, an FDA-approved proteasome inhibitor, prevents T cell exhaustion and improves therapeutic efficacy. Our findings identify a proteasome-guided haem signalling axis, governed by mitochondrial integrity, as a regulator of CD8 + T cell exhaustion and propose innovative therapeutic strategies that exploit this pathway to optimize adoptive cellular immunotherapy.

论文信息

作者
Xu Y、Shangguan Y、Chuang YM、Chang TH、Liu W、Peng JJ、Garnica J、Xie L
第一作者单位
Department of Oncology, University of Lausanne, Lausanne, Switzerland. xuyingxi@ihcams.ac.cn.Switzerland
通讯作者单位
Department of Oncology, University of Lausanne, Lausanne, Switzerland. ping-chih.ho@unil.ch.Switzerland
期刊
Nature2026 May
原文标识
PubMed 41851457 · DOI 10.1038/s41586-026-10250-y